Background: The EGFR is overexpressed in numerous cancers. So, it becomes one of the
most favorable drug targets. Single-acting EGFR inhibitors on prolong use induce resistance and side
effects. Inhibition of EGFR and/or its interacting proteins by dual/combined/multitargeted therapies can
deliver more efficacious drugs with less or no resistance.
Objective: The review delves deeper to cover the aspects of EGFR mediated endocytosis, leading to its
trafficking, internalization, and crosstalk(s) with HDACs.
Methods and Results: This review is put forth to congregate relevant literature evidenced on EGFR, its
impact on cancer prognosis, inhibitors, and its trafficking regulation by acetylation along with the current
strategies involved in targeting these proteins (EGFR and HDACs) successfully by involving
Conclusion: The current information on cross-talk of EGFR and HDACs would likely assist researchers
in designing and developing dual or multitargeted inhibitors through combining the required pharmacophores.